Clinical and Economic Consequences of a First Major Bleeding Event in Patients Treated with Direct Factor Xa Inhibitors in Spain: A Long-Term Observational Study

被引:0
|
作者
Escobar, Carlos [1 ]
Palacios, Beatriz [2 ]
Villarreal, Miriam [2 ]
Gutierrez, Martin [2 ]
Capel, Margarita [3 ]
Aranda, Unai [4 ]
Hernandez, Ignacio [5 ]
Garcia, Maria [5 ]
Lledo, Laura [5 ]
Arenillas, Juan F. [6 ,7 ]
机构
[1] Univ Hosp La Paz, Dept Cardiol, Madrid 28046, Spain
[2] AstraZeneca, BioPharmaceut Med, Madrid 28050, Spain
[3] AstraZeneca, BioPharmaceut Corp Affairs & Market Access, Madrid 28050, Spain
[4] AstraZeneca, BioPharmaceut Med, Global Med Affairs, Gaithersburg, MD 20878 USA
[5] Atrys Hlth, Madrid 28002, Spain
[6] Hosp Clin Univ, Comprehens Stroke Ctr, Neurol Dept, Valladolid 47003, Spain
[7] Univ Valladolid, Dept Med, Clin Neurosci Res Grp, Valladolid 47003, Spain
关键词
atrial fibrillation; cost; direct oral anticoagulants; healthcare resource utilization; major bleeding; reversal agents; venous thromboembolism; ORAL ANTICOAGULANTS; ATRIAL-FIBRILLATION; WARFARIN; RIVAROXABAN; GUIDELINE; APIXABAN; EDOXABAN; SAFETY;
D O I
10.3390/jcm13144253
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims: Our aims were to describe the clinical characteristics, adverse clinical events, healthcare resource utilization (HCRU) and costs of patients with major bleeding during direct Factor Xa inhibitor (FXai) use. Methods: This is a retrospective cohort study that included secondary data from computerized health records of seven Spanish Autonomous Communities. Patients with a first major bleeding during treatment with a direct FXai were analyzed during a 3-year period. Results: Of 8972 patients taking a direct FXai, 470 (5.24%) had major bleeding (mean age (SD) 77.93 (9.71) years, 61.06% women). The most frequent indications for using FXais were atrial fibrillation (78.09%) and venous thromboembolism (17.66%). Among those with major bleeding, 88.94% presented with gastrointestinal bleeding, 6.81% intracranial bleeding, 2.13% trauma-related bleeding and 4.26% other major bleeding. Prothrombin complex concentrates were used in 63.19%, followed by transfusion of blood products (20.21%) and Factor VIIa (7.66%). In total, 4.26% of patients died in the hospital due to the first major bleeding. At the study end (after 3-year follow-up), 28.94% of the patients had died, 12.34% had a myocardial infarction and 9.15% an ischemic stroke. At year 3, overall bleeding cost was EUR 5,816,930.5, of which 79.74% accounted for in-hospital costs to treat the bleeding episode. Conclusions: Despite the use of replacement agents being high, major events were common, with a 29% mortality at the end of the follow up, and HCRU and costs were high, evidencing the need for new reversal treatment strategies.
引用
收藏
页数:16
相关论文
共 50 条
  • [41] Adherence to direct or vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: a long-term observational study
    Salmasi, Shahrzad
    Safari, Abdollah
    De Vera, Mary A.
    Hoegg, Tanja
    Lynd, Larry D.
    Koehoorn, Mieke
    Barry, Arden R.
    Andrade, Jason G.
    Deyell, Marc W.
    Rush, Kathy L.
    Zhao, Yinshan
    Loewen, Peter
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2024, 57 (03) : 437 - 444
  • [42] Clinical characteristics of patients with takotsubo syndrome recurrence: An observational study with long-term follow- up
    Arcari, Luca
    Cacciotti, Luca
    Limite, Luca Rosario
    Russo, Domitilla
    Sclafani, Matteo
    Semeraro, Raffaella
    Ansalone, Gerardo
    Volpe, Massimo
    Autore, Camillo
    Musumeci, Maria Beatrice
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2021, 329 : 23 - 27
  • [43] Surgery and invasive procedures in patients on long-term treatment with direct oral anticoagulants: Thrombin or factor-Xa inhibitors. Recommendations of the Working Group on perioperative haemostasis and the French Study Group on thrombosis and haemostasis
    Sie, Pierre
    Samama, Charles M.
    Godier, Anne
    Rosencher, Nadia
    Steib, Annick
    Llau, Juan V.
    Van der Linden, Philippe
    Pernod, Gilles
    Lecompte, Thomas
    Gouin-Thibault, Isabelle
    Albaladejo, Pierre
    ARCHIVES OF CARDIOVASCULAR DISEASES, 2011, 104 (12) : 669 - 676
  • [44] Predictive Value of Chest HRCT Patterns for Respiratory Adverse Event Among RA Patients Treated with Biological Therapy: Long-Term Results from an Observational Study
    Matsumoto, Takuya
    Kojima, Toshihisa
    Takahashi, Nobunori
    Asai, Shuji
    Asai, Nobuyuki
    Watanabe, Tatsuo
    Kobayakawa, Tomonori
    Ishiguro, Naoki
    Iwano, Shingo
    Ito, Satoru
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [45] First-time postmenopausal bleeding as a clinical marker of long-term cancer risk: A Danish Nationwide Cohort Study
    Maria B. Bengtsen
    Katalin Veres
    Mette Nørgaard
    British Journal of Cancer, 2020, 122 : 445 - 451
  • [46] First-time postmenopausal bleeding as a clinical marker of long-term cancer risk: A Danish Nationwide Cohort Study
    Bengtsen, Maria B.
    Veres, Katalin
    Norgaard, Mette
    BRITISH JOURNAL OF CANCER, 2020, 122 (03) : 445 - 451
  • [47] Long-term follow-up of secondary amyloidosis patients treated with tumor necrosis factor inhibitor therapy A STROBE-compliant observational study
    Esatoglu, Sinem Nihal
    Hatemi, Gulen
    Ugurlu, Serdal
    Gokturk, Aycan
    Tascilar, Koray
    Ozdogan, Huri
    MEDICINE, 2017, 96 (34)
  • [48] Long-term Clinical and Cost Outcomes of a Pharmacist-managed Risk Factor Management Clinic in Singapore: An Observational Study
    Tan, She Hui
    Kng, Kwee Keng
    Lim, Sze Mian
    Chan, Alexandre
    Kong, Jason Kwok
    Lee, Joyce Yu-Chia
    CLINICAL THERAPEUTICS, 2017, 39 (12) : 2355 - 2365
  • [49] Independent Clinical Impacts of Procedural Complexity on Ischemic and Bleeding Events in Patients with Acute Myocardial Infarction: Long-Term Clinical Study
    Lee, Kwan Yong
    Hwang, Byung-Hee
    Lim, Sungmin
    Kim, Chan Jun
    Choo, Eun-Ho
    Lee, Seung Hoon
    Kim, Jin-Jin
    Choi, Ik Jun
    Oh, Gyu Chul
    Yang, In-Ho
    Yoo, Ki Dong
    Chung, Wook Sung
    Ahn, Youngkeun
    Jeong, Myung Ho
    Chang, Kiyuk
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (16)
  • [50] Long-term scarring outcomes and safety of patients treated with NovoSorbR⠂ Biodegradable Temporizing Matrix (BTM): An observational cohort study
    Lo, C. H.
    Wagstaff, M. J. D.
    Barker, T. M.
    Damkat-Thomas, L.
    Salerno, S.
    Holden, D.
    Concannon, E.
    Heath, K.
    Coghlan, P.
    Cleland, H.
    JPRAS OPEN, 2023, 37 : 42 - 51